Viral Conjunctivitis - Pipeline Review, H2 2017

SKU ID : GMD-11218075 | Publishing Date : 22-Aug-2017 | No. of pages : 33

Detailed TOC of Viral Conjunctivitis - Pipeline Review, H2 2017

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Viral Conjunctivitis - Overview
Viral Conjunctivitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Viral Conjunctivitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Viral Conjunctivitis - Companies Involved in Therapeutics Development
Adenovir Pharma AB
NanoViricides Inc
Panoptes Pharma GesmbH
Shire Plc
Viral Conjunctivitis - Drug Profiles
APD-209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APD-514 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EKCCide-I - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OKG-0301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHP-640 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Viral Conjunctivitis - Dormant Projects
Viral Conjunctivitis - Discontinued Products
Viral Conjunctivitis - Product Development Milestones
Featured News & Press Releases
Oct 11, 2012: Adenovir Pharma Announces Completion Of Phase I Study Of APD -209 To Treat Epidemic Keratoconjunctivitis
Aug 22, 2011: Researchers Discover New Drug To Treat Epidemic Keratoconjuntivitis
May 05, 2010: Foresight Biotherapeutics, Inc 's Drug FST-100 Reduces Infectious Adenoviral Titers And Improves Clinical Signs in Conjunctivitis Model
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Figures, Tables and Charts Available in Viral Conjunctivitis - Pipeline Review, H2 2017

List of Tables
Number of Products under Development for Viral Conjunctivitis, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Viral Conjunctivitis - Pipeline by Adenovir Pharma AB, H2 2017
Viral Conjunctivitis - Pipeline by NanoViricides Inc, H2 2017
Viral Conjunctivitis - Pipeline by Panoptes Pharma GesmbH, H2 2017
Viral Conjunctivitis - Pipeline by Shire Plc, H2 2017
Viral Conjunctivitis - Dormant Projects, H2 2017
Viral Conjunctivitis - Discontinued Products, H2 2017